Comparison of the Intestinal Drug Permeation and Accumulation Between Normal Human Intestinal Tissues and Human Intestinal Tissues With Ulcerative Colitis

被引:8
作者
Nakai, Daisuke [1 ]
Miyake, Masateru [1 ,2 ]
Hashimoto, Ayako [2 ]
机构
[1] Uppsala Univ, Dept Pharm, Husargatan 3, S-75123 Uppsala, Sweden
[2] Otsuka Pharmaceut Co Ltd, Qual Assurance Sect, Qual Assurance Dept, Headquarters Prod Safety & Qual Assurance, Matsudani Itano, Tokushima 7790195, Japan
关键词
human absorption; ulcerative colitis (UC); human tissues; transport index (TI); autopsy grade; USSING CHAMBER SYSTEM; PERMEABILITY; ABSORPTION; PREDICTION;
D O I
10.1016/j.xphs.2019.12.015
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The purpose of this study was to examine drug absorption profile utilizing human intestinal tissues from ulcerative colitis (UC) patients and to compare with normal tissues from intestinal cancer patients. Human intestinal tissues from UC and cancer patients mounted in a mini-Ussing chamber were used to evaluate the permeation of drugs, including FD-4, a very low permeable marker, rebamipide, a low permeable marker, and metoprolol, a high permeable marker. The transport index, an index of sum of permeated and tissue-accumulated molecules, of the model drugs was in accordance with their absorption rank order, and was almost kept constant irrespective of autopsy grade based on tissue fibrosis. On the other hand, UC tissues of grade 2 showed the decreased X-corr, an index of permeated amount of molecules and increased T-corr, an index of tissue-accumulated molecules for every tested compound. Our finding of the transport characteristics in intestinal tissues of severe UC patients in mini-Ussing chamber system demonstrated that autopsy grade of UC patients did not drastically change membrane permeability of the tested compounds. Furthermore, it was suggested that morphological changes of intestinal tissues caused by fibrosis led to limited permeation and subsequently increased accumulation with little change of total absorption. (C) 2019 American Pharmacists Association (R) . Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:1623 / 1626
页数:4
相关论文
共 15 条
  • [1] 51CrEDTA colonic permeability and therapy response in patients with ulcerative colitis
    Arslan, G
    Atasever, T
    Cindoruk, M
    Yildirim, IS
    [J]. NUCLEAR MEDICINE COMMUNICATIONS, 2001, 22 (09) : 997 - 1001
  • [2] Increased small intestinal permeability in ulcerative colitis: Rather genetic than environmental and a risk factor for extensive disease?
    Buening, Carsten
    Geissler, Nora
    Prager, Matthias
    Sturm, Andreas
    Baumgart, Daniel C.
    Buettner, Janine
    Buehner, Sabine
    Haas, Verena
    Lochs, Herbert
    [J]. INFLAMMATORY BOWEL DISEASES, 2012, 18 (10) : 1932 - 1939
  • [3] Dysregulation of Mucosal Membrane Transporters and Drug-Metabolizing Enzymes in Ulcerative Colitis
    Erdmann, Pascal
    Bruckmueller, Henrike
    Martin, Paul
    Busch, Diana
    Haenisch, Sierk
    Mueller, Janett
    Wiechowska-Kozlowska, Anna
    Partecke, Lars Ivo
    Heidecke, Claus-Dieter
    Cascorbi, Ingolf
    Drozdzik, Marek
    Oswald, Stefan
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 108 (02) : 1035 - 1046
  • [4] Fibrosis in ulcerative colitis is directly linked to severity and chronicity of mucosal inflammation
    Gordon, I. O.
    Agrawal, N.
    Willis, E.
    Goldblum, J. R.
    Lopez, R.
    Allende, D.
    Liu, X.
    Patil, D. Y.
    Yerian, L.
    El-Khider, F.
    Fiocchi, C.
    Rieder, F.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 47 (07) : 922 - 939
  • [5] Pediatric Crohn disease patients exhibit specific ileal transcriptome and microbiome signature
    Haberman, Yael
    Tickle, Timothy L.
    Dexheimer, Phillip J.
    Kim, Mi-Ok
    Tang, Dora
    Karns, Rebekah
    Baldassano, Robert N.
    Noe, Joshua D.
    Rosh, Joel
    Markowitz, James
    Heyman, Melvin B.
    Griffiths, Anne M.
    Crandall, Wallace V.
    Mack, David R.
    Baker, Susan S.
    Huttenhower, Curtis
    Keljo, David J.
    Hyams, Jeffrey S.
    Kugathasan, Subra
    Walters, Thomas D.
    Aronow, Bruce
    Xavier, Ramnik J.
    Gevers, Dirk
    Denson, Lee A.
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2014, 124 (08) : 3617 - 3633
  • [6] Simultaneous Prediction of Intestinal Absorption and Metabolism Using the Mini-Ussing Chamber System
    Kondo, Satoshi
    Miyake, Masateru
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 108 (01) : 763 - 769
  • [7] The sugar permeability test reflects disease activity in children and adolescents with inflammatory bowel disease
    Miki, K
    Moore, DJ
    Butler, RN
    Southcott, E
    Couper, RTL
    Davidson, GP
    [J]. JOURNAL OF PEDIATRICS, 1998, 133 (06) : 750 - 754
  • [8] Evaluation of intestinal metabolism and absorption using the Ussing chamber system equipped with intestinal tissue from rats and dogs
    Miyake, Masateru
    Kondo, Satoshi
    Koga, Toshihisa
    Yoda, Noriaki
    Nakazato, Satoru
    Emoto, Chie
    Mukai, Tadashi
    Toguchi, Hajime
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2018, 122 : 49 - 53
  • [9] Effect of proinflammatory cytokine IL-6 on efflux transport of rebamipide in Caco-2 cells
    Miyake, Masateru
    Nakai, Daisuke
    [J]. XENOBIOTICA, 2017, 47 (09) : 821 - 824
  • [10] Prediction of drug intestinal absorption in human using the Ussing chamber system: A comparison of intestinal tissues from animals and humans
    Miyake, Masateru
    Koga, Toshihisa
    Kondo, Satoshi
    Yoda, Noriaki
    Emoto, Chie
    Mukai, Tadashi
    Toguchi, Hajime
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2017, 96 : 373 - 380